389 related articles for article (PubMed ID: 34203935)
1. The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era.
Miazek-Zapala N; Slusarczyk A; Kusowska A; Zapala P; Kubacz M; Winiarska M; Bobrowicz M
Cells; 2021 Jun; 10(6):. PubMed ID: 34203935
[TBL] [Abstract][Full Text] [Related]
2. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
3. Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.
Xiong Y; Bensoussan D; Decot V
Transfus Med Rev; 2015 Oct; 29(4):259-67. PubMed ID: 26282736
[TBL] [Abstract][Full Text] [Related]
4. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
5. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
6. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
7. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment of graft-versus-host disease with immunomodulatory cells.
Yu Q; Wang H; Zhang L; Wei W
Int Immunopharmacol; 2021 Mar; 92():107349. PubMed ID: 33486323
[TBL] [Abstract][Full Text] [Related]
9. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
10. Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.
Ghosh A; Politikos I; Perales MA
Curr Opin Oncol; 2017 Nov; 29(6):474-483. PubMed ID: 28872470
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
12. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
13. Toxicities associated with immunotherapies for hematologic malignancies.
Leick MB; Maus MV
Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
[TBL] [Abstract][Full Text] [Related]
14. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
15. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
16. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
18. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.
Mochel JP; Ekker SC; Johannes CM; Jergens AE; Allenspach K; Bourgois-Mochel A; Knouse M; Benzekry S; Wierson W; LeBlanc AK; Kenderian SS
AAPS J; 2019 Apr; 21(3):50. PubMed ID: 30963322
[TBL] [Abstract][Full Text] [Related]
19. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
